US 11,806,431 B2
Formulations and methods for contemporaneous stabilization of active proteins during spray drying and storage
Qiyong Peter Liu, Newton, MA (US); Junqing Cui, West Roxbury, MA (US); Rud Karly Lucien, Lynn, MA (US); Ryan Carney, Hudson, NH (US); Jihae Sohn, Brighton, MA (US); Michelle Arya, Medford, MA (US); and Abdul W. Khan, Lindenhurst, IL (US)
Assigned to Velico Medical, Inc., Beverly, MA (US)
Filed by Velico Medical Inc., Beverly, MA (US)
Filed on Jun. 2, 2021, as Appl. No. 17/337,306.
Application 17/337,306 is a continuation of application No. 15/383,201, filed on Dec. 19, 2016, granted, now 11,052,045.
Application 15/383,201 is a continuation of application No. 14/858,539, filed on Sep. 18, 2015, granted, now 9,545,379, issued on Jan. 17, 2017.
Claims priority of provisional application 62/052,689, filed on Sep. 19, 2014.
Prior Publication US 2021/0290545 A1, Sep. 23, 2021
Int. Cl. A61K 9/16 (2006.01); F26B 3/06 (2006.01); F26B 3/12 (2006.01); F26B 5/04 (2006.01); A61K 35/16 (2015.01); B01J 19/06 (2006.01); F26B 3/04 (2006.01); F26B 5/06 (2006.01); B65D 81/26 (2006.01); B65D 51/30 (2006.01)
CPC A61K 9/1682 (2013.01) [A61K 9/16 (2013.01); A61K 9/1617 (2013.01); A61K 9/1688 (2013.01); A61K 35/16 (2013.01); B01J 19/06 (2013.01); F26B 3/04 (2013.01); F26B 3/06 (2013.01); F26B 3/12 (2013.01); F26B 5/04 (2013.01); B01J 2219/00177 (2013.01); B65D 51/30 (2013.01); B65D 81/266 (2013.01); F26B 5/065 (2013.01)] 30 Claims
 
1. A reconstituted previously dried plasma product for human transfusion made by the method of:
a) combining i) plasma with ii) one or more stable acidic substances, wherein said one or more stable acidic substances is an acid or acidic salt that effectuates a pH and is physiologically suitable for addition to plasma being dried or physiologically suitable for subjects into which reconstituted plasma is transfused, to thereby create a formulated plasma so that the pH of formulated plasma is between about 5.5 and 7.2,
b) drying the formulated plasma to thereby obtain a dried formulated plasma; and
c) reconstituting said dried formulated plasma with sterile water or alkaline solution to thereby obtain a reconstituted dried plasma product for human transfusion.